Valanx Biotech is a university spin-out offering a patented method for high-efficiency protein conjugation for cancer drug targeting and other uses. Through the power of synthetic biology and genetic-code expansion, we have developed a novel site-specific protein conjugation platform that allows precise control over a conjugation site and the number of conjugations on the protein of interest.